Video

Upperton Pharma: Capabilities Update November 2026: Bioavailability/ Solubility

Poor aqueous solubility frequently limits human exposure and threatens dose feasibility in early clinical trials. Choosing an incompatible formulation early wastes scarce active pharmaceutical ingredients (API), time, and capital. A systematic, data-driven screening approach evaluates a molecule’s Biopharmaceutics Classification System (BCS) profile using just one to five grams of API, testing scalable pathways like micronization, lipidic semi-solid matrices, co-micronization, and spray-dried amorphous solid dispersions within five to eight weeks. By pairing rapid in vitro dissolution screening with in vivo pharmacokinetic studies, development teams can identify a robust, scalable lead candidate—such as a spray-dried dispersion that increases bioavailability 12-fold and cuts patient dose burdens from 12 grams to under one gram.

Watch the full presentation to see how rapid formulation screening and integrated manufacturing capabilities streamline the path from initial proof of concept to clinical trials.

Access The Video!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma